Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40J1L | ISIN: CA22112H1010 | Ticker-Symbol: ET8
München
31.03.25
08:01 Uhr
2,860 Euro
-0,040
-1,38 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COSCIENS BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
COSCIENS BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,5802,74020:57

Aktuelle News zur COSCIENS BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.03.Why COSCIENS Biopharma Inc. (CSCI) Went Down On Thursday?6
20.03.COSCIENS Biopharma Inc. Announces Possible Delay in Filing Year-End Reporting Documents362Toronto, Ontario--(Newsfile Corp. - March 19, 2025) - COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a life science company which develops and commercializes a diversified...
► Artikel lesen
20.03.Cosciens Biopharma Inc: Cosciens Biopharma may delay filing 2024 financials3
COSCIENS BIOPHARMA Aktie jetzt für 0€ handeln
13.03.Cosciens Biopharma Inc: Cosciens starts phase 2a study on avenanthramides5
13.03.COSCIENS Biopharma Advances Avenanthramide Clinical Trial To Phase 2a For Inflammation Treatment5
13.03.COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer1
13.03.COSCIENS Biopharma Inc. Announces Successful Phase 1 Results Supporting Initiation of Phase 2a Clinical Efficacy Trial with Avenanthramides as a Potential Anti-Inflammatory Product116No significant clinical adverse event observed in Phase 1clinical studyPharmacokinetic profile established and range of doses selected for Phase 2a Clinical Efficacy StudyFirst patient expected to...
► Artikel lesen
23.12.24Cosciens Biopharma Inc: Cosciens talks cost-cutting in 2024, focus for 202511
23.12.24COSCIENS Biopharma halts investment in macimorelin; CMO to depart17
23.12.24COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization296Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations...
► Artikel lesen
23.12.24COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer-
12.11.24COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs292Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE...
► Artikel lesen
12.11.24COSCIENS Biopharma Inc. - 6-K, Report of foreign issuer-
08.10.24Cosciens Biopharma Inc: Cosciens Biopharma director Egbert resigns6
08.10.24COSCIENS Biopharma strukturiert Vorstand um17
08.10.24COSCIENS Biopharma reshuffles board of directors 5
08.10.24COSCIENS Biopharma Inc.: COSCIENS Biopharma Announces Change to Board of Directors1
02.10.24Cosciens Biopharma Inc: Cosciens Biopharma appoints Labbe to board2
23.09.24COSCIENS Biopharma Inc. Provides Updates on Merger Integration, Management Succession Plans and Ongoing Development Programs174TORONTO, ONTARIO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI) ("COSCIENS" or the "Company"), a specialty biopharmaceutical company developing and commercializing...
► Artikel lesen
27.08.24COSCIENS Biopharma Inc. Announces Top-Line Results of Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency341- Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol - Potent growth hormone release following macimorelin stimulation - Safety...
► Artikel lesen
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,16